Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCUSS: Discontinuation of CDK4/6 Inhibitors in Metastatic Breast Cancer
NCT06207734Phase 2Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-free survival rate 12 months after randomization. Started Jan 2024; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06207734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207734.